Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy

Area of Science:

• Oncology
• Medical treatment

Background:

• Targeted agents have improved outcomes in metastatic clear cell renal cell carcinoma (ccRCC).
• Evasive resistance mechanisms lead to disease progression, necessitating further therapies.
• Optimal sequencing of treatments after first-line therapy failure in ccRCC is not well-established.

Purpose of the Study:

• To review current understanding of treatment sequencing in metastatic ccRCC.
• To discuss factors influencing the choice of subsequent therapies.
• To explore options for treatment beyond second-line therapy.

Main Methods:

• Review of randomized clinical trials and clinical practice considerations.
• Analysis of prognostic and predictive factors, and resistance mechanisms.
• Discussion of retrospective data on treatment rechallenge and local therapies.

Main Results:

• Everolimus and axitinib are standard after first-line VEGF-TKI failure; sorafenib is an option.
• Treatment decisions are influenced by prior drug exposure, prognostic factors, and resistance.
• Evidence for treatment beyond second-line is limited, with retrospective data guiding choices.

Conclusions:

• Sequencing targeted therapies in metastatic ccRCC requires careful consideration of multiple factors.
• Treatment beyond second-line is challenging and may involve rechallenge or local approaches.
• Optimizing outcomes in advanced ccRCC involves strategic sequencing and individualized treatment plans.